l carnitine for pre workout BulkSupplements.com L-Carnitine L-Tartrate Powder - Fat Burner Men - Fat Burners For Women - Supplement - Weight Loss - Weight Loss Powder (500 Grams Made with high Alpha Supps L Carnitine Liquid

Description

Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Application filed by United States Department of Commerce, US Department of Health and Human Services filed Critical United States Department of Commerce Publication of EP0502054A1 publication Critical patent/EP0502054A1/fr Publication of EP0502054A4 publication Critical patent/EP0502054A4/en Application granted granted Critical Publication of EP0502054B1 publication Critical patent/EP0502054B1/fr Anticipated expiration legal-status Critical Expired - Lifetime legal-status Critical Current Links Espacenet EPO GPI EP Register Global Dossier Discuss RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 249 108010024636 Glutathione Proteins 0.000 title claims abstract description 71 210000004072 lung Anatomy 0.000 title claims abstract description 48 238000000034 method Methods 0.000 title claims abstract description 27 230000003190 augmentative effect Effects 0.000 title claims abstract description 10 229960003180 glutathione Drugs 0.000 title claims description 107 239000000443 aerosol Substances 0.000 title claims description 51 238000002360 preparation method Methods 0.000 title description 6 FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11 239000000203 mixture Substances 0.000 claims description 9 208000035475 disorder Diseases 0.000 claims description 6 239000003937 drug carrier Substances 0.000 claims description 6 201000010099 disease Diseases 0.000 claims description 5 230000005980 lung dysfunction Effects 0.000 claims description 5 239000008194 pharmaceutical composition Substances 0.000 claims description 5 239000011780 sodium chloride Substances 0.000 claims description 5 231100000252 nontoxic Toxicity 0.000 claims description 4 230000003000 nontoxic effect Effects 0.000 claims description 4 238000004519 manufacturing process Methods 0.000 claims description 2 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract description 7 208000036971 interstitial lung disease 2 Diseases 0.000 abstract description 7 208000030507 AIDS Diseases 0.000 abstract description 4 201000003883 Cystic fibrosis Diseases 0.000 abstract description 3 239000012530 fluid Substances 0.000 description 20 210000002751 lymph Anatomy 0.000 description 17 210000002700 urine Anatomy 0.000 description 14 241001494479 Pecora Species 0.000 description 13 210000002345 respiratory system Anatomy 0.000 description 13 LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12 238000012387 aerosolization Methods 0.000 description 11 238000001990 intravenous administration Methods 0.000 description 10 108010053070 Glutathione Disulfide Proteins 0.000 description 9 YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 9 KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7 238000011156 evaluation Methods 0.000 description 6 229910000160 potassium phosphate Inorganic materials 0.000 description 6 235000011009 potassium phosphates Nutrition 0.000 description 6 KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 5 239000007800 oxidant agent Substances 0.000 description 5 239000000243 solution Substances 0.000 description 5 231100000419 toxicity Toxicity 0.000 description 5 230000001988 toxicity Effects 0.000 description 5 239000008280 blood Substances 0.000 description 4 210000004369 blood Anatomy 0.000 description 4 230000007812 deficiency Effects 0.000 description 4 239000000463 material Substances 0.000 description 4 239000006199 nebulizer Substances 0.000 description 4 230000002685 pulmonary effect Effects 0.000 description 4 241001465754 Metazoa Species 0.000 description 3 OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3 239000003963 antioxidant agent Substances 0.000 description 3 230000008021 deposition Effects 0.000 description 3 239000012895 dilution Substances 0.000 description 3 238000010790 dilution Methods 0.000 description 3 LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3 230000000694 effects Effects 0.000 description 3 230000003434 inspiratory effect Effects 0.000 description 3 230000001590 oxidative effect Effects 0.000 description 3 239000002953 phosphate buffered saline Substances 0.000 description 3 230000008569 process Effects 0.000 description 3 238000002560 therapeutic procedure Methods 0.000 description 3 241000282412 Homo Species 0.000 description 2 241000725303 Human immunodeficiency virus Species 0.000 description 2 206010061218 Inflammation Diseases 0.000 description 2 HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2 230000002411 adverse Effects 0.000 description 2 230000003078 antioxidant effect Effects 0.000 description 2 238000003556 assay Methods 0.000 description 2 206010006451 bronchitis Diseases 0.000 description 2 230000008859 change Effects 0.000 description 2 238000002474 experimental method Methods 0.000 description 2 229940045883 glutathione disulfide Drugs 0.000 description 2 210000004969 inflammatory cell Anatomy 0.000 description 2 230000004054 inflammatory process Effects 0.000 description 2 210000004731 jugular vein Anatomy 0.000 description 2 210000003141 lower extremity Anatomy 0.000 description 2 238000005259 measurement Methods 0.000 description 2 230000009467 reduction Effects 0.000 description 2 210000001519 tissue Anatomy 0.000 description 2 239000003981 vehicle Substances 0.000 description 2 210000003462 vein Anatomy 0.000 description 2 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1 GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1 229930024421 Adenine Natural products 0.000 description 1 206010067484 Adverse reaction Diseases 0.000 description 1 206010002091 Anaesthesia Diseases 0.000 description 1 201000001178 Bacterial Pneumonia Diseases 0.000 description 1 206010006458 Bronchitis chronic Diseases 0.000 description 1 206010016654 Fibrosis Diseases 0.000 description 1 206010017533 Fungal infection Diseases 0.000 description 1 108010063907 Glutathione Reductase Proteins 0.000 description 1 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1 241000589248 Legionella Species 0.000 description 1 206010024179 Legionella infections Diseases 0.000 description 1 208000019693 Lung disease Diseases 0.000 description 1 208000032376 Lung infection Diseases 0.000 description 1 206010062207 Mycobacterial infection Diseases 0.000 description 1 241000204031 Mycoplasma Species 0.000 description 1 206010028470 Mycoplasma infections Diseases 0.000 description 1 208000031888 Mycoses Diseases 0.000 description 1 GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1 208000001388 Opportunistic Infections Diseases 0.000 description 1 108090000854 Oxidoreductases Proteins 0.000 description 1 229910019142 PO4 Inorganic materials 0.000 description 1 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1 238000000692 Student's t-test Methods 0.000 description 1 XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1 230000002159 abnormal effect Effects 0.000 description 1 239000002253 acid Substances 0.000 description 1 230000001154 acute effect Effects 0.000 description 1 229960000643 adenine Drugs 0.000 description 1 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1 230000006838 adverse reaction Effects 0.000 description 1 230000037005 anaesthesia Effects 0.000 description 1 QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1 230000003416 augmentation Effects 0.000 description 1 230000001580 bacterial effect Effects 0.000 description 1 210000004082 barrier epithelial cell Anatomy 0.000 description 1 230000009286 beneficial effect Effects 0.000 description 1 230000037396 body weight Effects 0.000 description 1 239000004202 carbamide Substances 0.000 description 1 208000007451 chronic bronchitis Diseases 0.000 description 1 230000015271 coagulation Effects 0.000 description 1 238000005345 coagulation Methods 0.000 description 1 230000007123 defense Effects 0.000 description 1 230000002950 deficient Effects 0.000 description 1 238000013461 design Methods 0.000 description 1 239000012153 distilled water Substances 0.000 description 1 238000009826 distribution Methods 0.000 description 1 229940079593 drug Drugs 0.000 description 1 239000003814 drug Substances 0.000 description 1 230000004890 epithelial barrier function Effects 0.000 description 1 230000008378 epithelial damage Effects 0.000 description 1 210000000981 epithelium Anatomy 0.000 description 1 230000029142 excretion Effects 0.000 description 1 210000003414 extremity Anatomy 0.000 description 1 230000004761 fibrosis Effects 0.000 description 1 230000006870 function Effects 0.000 description 1 239000007789 gas Substances 0.000 description 1 BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1 229960003132 halothane Drugs 0.000 description 1 230000003116 impacting effect Effects 0.000 description 1 238000000338 in vitro Methods 0.000 description 1 238000011534 incubation Methods 0.000 description 1 238000002347 injection Methods 0.000 description 1 239000007924 injection Substances 0.000 description 1 239000007788 liquid Substances 0.000 description 1 230000001926 lymphatic effect Effects 0.000 description 1 231100000682 maximum tolerated dose Toxicity 0.000 description 1 238000012986 modification Methods 0.000 description 1 230000004048 modification Effects 0.000 description 1 238000012544 monitoring process Methods 0.000 description 1 210000004400 mucous membrane Anatomy 0.000 description 1 208000027531 mycobacterial infectious disease Diseases 0.000 description 1 239000001301 oxygen Substances 0.000 description 1 229910052760 oxygen Inorganic materials 0.000 description 1 238000003921 particle size analysis Methods 0.000 description 1 NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1 239000010452 phosphate Substances 0.000 description 1 230000036470 plasma concentration Effects 0.000 description 1 230000009325 pulmonary function Effects 0.000 description 1 238000011084 recovery Methods 0.000 description 1 238000005070 sampling Methods 0.000 description 1 229920000260 silastic Polymers 0.000 description 1 238000010561 standard procedure Methods 0.000 description 1 239000006228 supernatant Substances 0.000 description 1 230000008685 targeting Effects 0.000 description 1 238000012360 testing method Methods 0.000 description 1 AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1 231100000331 toxic Toxicity 0.000 description 1 230000002588 toxic effect Effects 0.000 description 1 210000003437 trachea Anatomy 0.000 description 1 230000001052 transient effect Effects 0.000 description 1 231100000402 unacceptable toxicity Toxicity 0.000 description 1 238000009423 ventilation Methods 0.000 description 1 208000009421 viral pneumonia Diseases 0.000 description 1 238000011179 visual inspection Methods 0.000 description 1 239000003643 water by type Substances 0.000 description 1 Images Classifications AHUMAN NECESSITIES A61MEDICAL OR VETERINARY SCIENCE

After another 24 days, swift confluence of these vesicles is observed and finally, approximately 712 days after rash onset, these vesicles are normally dried-out